On May 13, 2025, the CDC issued a national patient safety alert. Investigators had traced more than 40 confirmed bloodstream infections to a single source: contaminated, nonsterile, multi-use ultrasound gel used during percutaneous procedures. The pathogen was Paraburkholderia fungorum. The contaminated products — MediChoice® — had been used in facilities across the country. The bacteria entered patients through needle puncture sites during IV line placements, biopsies, and paracentesis procedures, all of which are considered routine.

The outbreak, later presented at the Association for Professionals in Infection Control and Epidemiology (APIC) Annual Conference in 2026 via whole genome sequencing confirmation, was dramatic enough. But it was only one of four distinct, coexisting failures in how American healthcare facilities handle ultrasound disinfection. The others are quieter — slower-burning — but they may be putting even more patients at risk while simultaneously destroying some of the most expensive equipment in the hospital.

Four Simultaneous Failures

The research literature, the CDC alert, and the newly revised AIUM 2025 guidelines collectively document at least four distinct ways that ultrasound disinfection protocols fail — often simultaneously, in the same facility, on the same day.

The Gel Problem: When “Clean” Gel Isn’t

Ultrasound gel has never been treated with the same caution as other medical consumables. It’s applied to skin, acts as a coupling medium, and is wiped off — it has never seemed like a transmission risk. That assumption began to crack years ago with scattered case reports of bacterial contamination in nonsterile multi-use bottles, but it took the 2025 outbreak to force a reckoning.

The investigation, later presented at APIC 2026 with whole genome sequencing evidence, found that Paraburkholderia fungorum — an opportunistic environmental pathogen — had colonized multiple lots of commercially distributed gel. The bacteria survived in the product because nonsterile gel is not manufactured under the same controlled conditions as sterile medical supplies. Multi-use bottles, once opened, are routinely handled, set down on equipment surfaces, and left uncapped between patients.

The Equipment Problem: Alcohol Is Eating Your Probes

Ultrasound transducers are among the most expensive and mechanically precise devices in a clinical setting. A mid-range diagnostic probe runs $10,000 to $20,000. High-end transducers for cardiac or 4D imaging can reach $40,000 or more. And a large body of research — including a landmark study indexed on PubMed — has confirmed that a significant proportion of premature probe failures are caused not by patient handling, not by drops or impacts, but by the disinfectant used to clean them.

The mechanism is specific and predictable. Alcohol-based disinfectants — isopropyl alcohol, ethyl alcohol, and many “sanitizing” wipes sold without clear labeling — attack the adhesive layer that bonds the acoustic window to the transducer housing. This adhesive is critical: it seals the probe’s interior from the exterior environment. Once it degrades, the acoustic window begins to delaminate — to separate from the housing — and fluid can infiltrate the transducer assembly. At that point, the probe is typically unsalvageable.

Sodium hypochlorite (bleach), which was promoted in some COVID-era surface disinfection protocols, creates a different category of damage: corrosion of metal components, degradation of silicone and rubber cable jackets, and cracking of probe housings over time. Some facilities adopted bleach protocols during the pandemic without accounting for their effects on sensitive imaging equipment.

The HLD Problem: Low-Level Is Not Always Enough

The distinction between low-level disinfection (LLD) and high-level disinfection (HLD) exists for a reason. External ultrasound probes — those placed on the skin surface for abdominal, cardiac, vascular, or musculoskeletal imaging — come into contact with intact skin and require LLD between patients. Internal or endocavitary probes — transvaginal, transrectal, and transesophageal transducers — come into contact with mucous membranes and require HLD before each patient use, regardless of whether a probe cover is used.

This rule is clearly established. It is also widely violated.

A study published in PLOS ONE found that microbial contamination persisted on transvaginal ultrasound probes after standard low-level disinfection with quaternary ammonium compound wipes and chlorhexidine — even when probe covers had been used correctly. A separate analysis of high-risk HPV found that 2.5% of endocavitary probes still carried high-risk HPV strains after LLD. These are not rare pathogens. HPV types 16 and 18 are oncogenic — associated with cervical cancer. The transmission risk from inadequately reprocessed transvaginal probes is not theoretical.

The Automated HLD Problem: Not All Machines Deliver HLD

The category of automated high-level disinfection devices has expanded rapidly as hospitals sought to standardize and speed up endocavitary probe reprocessing. UV-C-based systems became particularly popular: compact, fast, and easy to use at point of care. A 2025 validation study published in ScienceDirect tested these devices against sporicidal efficacy benchmarks — and the results were troubling.

UV-C automated systems failed to achieve sporicidal efficacy. Hydrogen peroxide vapor and mist systems, by contrast, demonstrated consistent sporicidal performance. The practical implication: facilities using UV-C devices may believe their endocavitary probes are undergoing adequate HLD when they are not — leaving a gap between perceived compliance and actual patient protection.

The AIUM 2025 revision also introduced chlorine dioxide as an approved HLD agent for the first time, providing a point-of-care option with a two-minute kill time effective against HPV, C. difficile, M. tuberculosis, and bloodborne viruses — without requiring transport to central reprocessing or automated machinery.

The Correct Protocol: What the 2025 Evidence Demands

The Cost of Getting This Wrong

The four failures documented above are not edge cases in poorly resourced facilities. They are widespread, systemic, and documented in peer-reviewed literature, CDC bulletins, and professional society guidelines issued by the organizations whose entire mandate is setting safe standards. They coexist in well-funded academic medical centers and community clinics alike.

The contaminated gel problem is the most visible because it produced an outbreak large enough to trigger a national alert. But the equipment destruction problem may be more economically damaging in aggregate — one hospital replacing three or four transducers annually due to disinfectant incompatibility is spending $120,000 to $160,000 a year on a preventable problem. The endocavitary HPV persistence problem is harder to see because it doesn’t produce a discrete outbreak — it produces a diffuse, untraceable elevation in HPV transmission risk that never gets attributed to the probe that carried it.

The 2025 AIUM revision, the CDC gel alert, and the automated HLD validation data together represent something relatively rare in infection prevention: a convergence of new evidence, updated guidelines, and regulatory enforcement pressure all pointing in the same direction at the same time. Facilities that update their protocols now — sterile single-use gel, compatible quat-based surface wipes, validated HLD for all endocavitary probes, documentation — are not ahead of the curve. They are at the curve. The ones who wait will be behind it.